ALNY: Alnylam Pharmaceuticals, Inc.
About
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip Allen Sharp on June 14, 2002 and is headquartered in Cambridge, MA.
Current Value
$250.591 Year Return
Current Value
$250.591 Year Return
Key Details
Market Cap
$32.63B
P/E Ratio
-96.52
1Y Stock Return
46.36%
1Y Revenue Growth
21.54%
Dividend Yield
0.00%
Price to Book
1007.5
Strategies that include ALNY
Stock's related to ALNY
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| IONS | 47.75% | $5.70B | -29.85% | 0.00% |
| RXO | 43.48% | $4.83B | +36.50% | 0.00% |
| ARGX | 33.51% | $37.28B | +34.90% | 0.00% |
| DMRC | 29.59% | $739.44M | +2.07% | 0.00% |
| ARWR | 28.84% | $3.28B | +5.66% | 0.00% |
| LH | 28.70% | $20.13B | +8.39% | 1.19% |
| AUPH | 27.65% | $1.30B | +3.17% | 0.00% |
| ERII | 27.28% | $928.62M | -14.45% | 0.00% |
| BEAM | 26.72% | $2.34B | -4.28% | 0.00% |
| AMWL | 26.59% | $141.25M | -65.34% | 0.00% |
| MNKD | 25.64% | $1.82B | +75.73% | 0.00% |
| PSQH | 25.52% | $71.61M | -66.67% | 0.00% |
| NBIX | 25.22% | $12.75B | +8.03% | 0.00% |
| EVGO | 25.06% | $698.86M | +94.91% | 0.00% |
| REGN | 24.92% | $83.77B | -7.41% | 0.00% |
| PGEN | 24.83% | $266.19M | -25.50% | 0.00% |
| AMGN | 24.44% | $149.49B | +2.04% | 3.24% |
| PLRX | 24.41% | $943.84M | +7.48% | 0.00% |
| RCKT | 24.35% | $1.31B | -41.78% | 0.00% |
| SRPT | 23.70% | $12.22B | +48.57% | 0.00% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| SXI | -<0.01% | $2.53B | +51.66% | 0.58% |
| JKS | -0.01% | $1.27B | -25.65% | 0.00% |
| PAYC | -0.02% | $12.99B | +24.82% | 0.65% |
| LRCX | 0.02% | $101.02B | +10.57% | 10.62% |
| JBI | -0.03% | $1.07B | -30.29% | 0.00% |
| APPF | -0.05% | $9.30B | +32.36% | 0.00% |
| COIN | -0.05% | $75.71B | +114.33% | 0.00% |
| BROS | -0.06% | $6.20B | +98.83% | 0.00% |
| TSM | 0.06% | $1.01T | +100.39% | 1.14% |
| HAL | -0.07% | $27.73B | -15.55% | 2.10% |
| CRON | 0.09% | $791.35M | -5.48% | 0.00% |
| MFC | -0.09% | $56.62B | +62.90% | 3.60% |
| ASGN | 0.10% | $4.07B | -1.61% | 0.00% |
| KFY | -0.11% | $4.09B | +44.75% | 1.78% |
| FERG | 0.11% | $42.98B | +27.25% | 1.44% |
| TPL | -0.12% | $34.47B | +185.71% | 0.49% |
| SIBN | 0.13% | $560.71M | -28.77% | 0.00% |
| CRBG | -0.13% | $18.18B | +55.40% | 2.86% |
| TLYS | 0.13% | $141.11M | -40.46% | 0.00% |
| LIN | 0.13% | $218.89B | +13.05% | 0.91% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| SEG | -20.08% | $395.76M | +20.95% | 0.00% |
| RMD | -14.83% | $35.95B | +51.63% | 0.82% |
| CRVO | -14.09% | $86.58M | +13.90% | 0.00% |
| CBOE | -13.19% | $22.18B | +16.57% | 1.10% |
| CYRX | -13.15% | $384.57M | -50.26% | 0.00% |
| CPSH | -12.69% | $22.08M | -36.54% | 0.00% |
| PTMN | -12.23% | - | - | 16.45% |
| QCOM | -12.06% | $181.13B | +25.46% | 1.54% |
| SON | -11.96% | $5.12B | -7.14% | 3.97% |
| LAB | -11.59% | $722.18M | -23.32% | 0.00% |
| BAND | -10.22% | $580.74M | +74.61% | 0.00% |
| VSTA | -10.01% | $194.41M | -41.46% | 0.00% |
| BYRN | -10.00% | $412.04M | +204.99% | 0.00% |
| VNT | -9.98% | $5.90B | +14.47% | 0.25% |
| NTIC | -9.97% | $129.84M | +24.75% | 2.04% |
| DKNG | -9.70% | $21.42B | +18.12% | 0.00% |
| FROG | -9.54% | $3.44B | +9.18% | 0.00% |
| BBIO | -9.24% | $5.03B | -16.72% | 0.00% |
| ORN | -9.11% | $336.11M | +84.62% | 0.00% |
| PTVE | -9.10% | $2.44B | +11.57% | 2.92% |
ETF's related to ALNY
News
Yahoo
We recently compiled a list of the 10 High Growth Healthcare Stocks to Invest in Now. In this article, we are going to take a look at where Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) stands against the other high growth healthcare stocks. Global Healthcare Spending Trends and Investment Opportunities During lean economic times, investing in healthcare stocks […]
Yahoo
CAMBRIDGE, Mass., November 27, 2024--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Piper Sandler 36th Annual Healthcare Conference on Thursday, December 5, 2024 at 11:00 am ET at the Lotte New York Palace Hotel in New York City.
Yahoo
Kronos is cutting 83% of its workforce, while Idorsia is considering eliminating as many as 270 jobs. Elsewhere, PTC disclosed negative Phase 2 results for its ALS drug candidate utreloxastat.
Yahoo
ALNY reports submitting an sNDA in the United States, seeking the label expansion of Amvuttra to treat ATTR amyloidosis with cardiomyopathy.
Yahoo
BridgeBio Pharma snagged FDA approval for its rival to Pfizer's heart disease treatment, Vyndaqel. BridgeBio stock catapulted.
Yahoo
The United States market has shown robust performance, climbing by 2.2% over the past week with all sectors experiencing gains, and achieving a 32% increase over the last 12 months, while earnings are projected to grow by 15% annually. In this thriving environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation potential and scalability to capitalize on these favorable market conditions.
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.